LONDON, October 18, 2025 – AstraZeneca’s (AZN.L) Enhertu reduced breast cancer recurrence risk by 53% versus standard treatment in a pivotal trial. The Phase III results could expand the drug’s use into earlier-stage treatment, potentially boosting revenue for the pharmaceutical giant’s key oncology asset.
- Enhertu cut disease recurrence or death risk by 53%
- Over 92% of patients remained disease-free at three years
- Results support earlier-stage breast cancer treatment expansion
Trial Results and Market Impact
The DESTINY-Breast05 Phase III trial showed Enhertu significantly outperformed T-DM1, the current standard of care, in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy 1. More than 92% of patients treated with Enhertu were free of invasive disease at three years compared to the control group 2.
The results were presented at the European Society for Medical Oncology (ESMO) 2025 congress, marking a potential expansion of Enhertu’s treatment scope beyond advanced-stage cancer. Enhertu generated 2.9 billion in sales for AstraZeneca in 2024, making it one of the company’s fastest-growing oncology products.
Clinical Significance
The trial focused on patients who had residual disease after completing neoadjuvant chemotherapy, representing a high-risk population for cancer recurrence. Enhertu, developed jointly with Japan’s Daiichi Sankyo, is an antibody-drug conjugate that delivers chemotherapy directly to cancer cells expressing the HER2 protein 3.
Industry analysts said the data demonstrates “promise of Enhertu to move earlier” in breast cancer treatment, potentially capturing patients before their disease progresses to advanced stages 3. Early-stage treatment typically involves larger patient populations and longer treatment durations than advanced cancer therapy.
Regulatory and Commercial Outlook
AstraZeneca plans to submit these results to global regulatory authorities to seek approval for Enhertu in the adjuvant breast cancer setting. The drug currently holds approvals for HER2-positive metastatic breast cancer and has expanded to include cases where cancer returns within six months of completing early-stage treatment 6.
The positive trial results follow earlier data showing Enhertu’s effectiveness as a first-line treatment for metastatic breast cancer, broadening its potential commercial applications 8. Successful regulatory approval could significantly expand Enhertu’s addressable patient population and extend its patent protection timeline.
Competitive Landscape
The breast cancer treatment market has seen increased competition from antibody-drug conjugates, with companies like Gilead Sciences developing rival therapies. However, Enhertu’s demonstrated efficacy across multiple breast cancer settings positions it as a leading treatment option in the HER2-positive segment.
The trial results reinforce AstraZeneca’s strategy to expand successful oncology treatments into earlier disease stages, following similar approaches with other cancer drugs in its portfolio. This strategy aims to capture patients earlier in their treatment journey and potentially improve long-term outcomes.
Not investment advice. For informational purposes only.
References
1“Enhertu reduced the risk of disease recurrence or death by 53% vs T-DM1 in patients with high-risk HER2-positive early breast cancer”. AstraZeneca. Retrieved October 18, 2025.
2“ENHERTU (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs T-DM1”. AstraZeneca US. Retrieved October 18, 2025.
3“ESMO 2025: Data shows ‘promise of Enhertu to move earlier’ in breast cancer treatment”. The Pharma Letter. Retrieved October 18, 2025.
4“ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1”. Morningstar. Retrieved October 18, 2025.
5“ESMO 2025: Further findings on Enhertu in early breast cancer”. The Pharma Letter. Retrieved October 18, 2025.
6“Enhertu Shows Promise as First-Line Treatment for Metastatic Breast Cancer”. Verywell Health. Retrieved October 18, 2025.
7“Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer”. Cancer Letter. Retrieved October 18, 2025.
8“Enhertu and Trodelvy Show Promise for First-Line Metastatic Breast Cancer Treatment”. Cancer Health. Retrieved October 18, 2025.